Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival

Myocardial infarction accelerates breast cancer via innate immune reprogramming

(2020) Graeme J. Koelwyn et al.   NATURE MEDICINE

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

(2019) Alok A. Khorana et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thrombin signaling promotes pancreatic adenocarcinoma through PAR-1-dependent immune evasion

(2019) Yi Yang et al.   CANCER RESEARCH

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies

(2019) Ryo Sato et al.   Journal of Clinical Medicine

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

(2019) Nigel S. Key et al.   JOURNAL OF CLINICAL ONCOLOGY

Venous thromboembolism in breast cancer patients receiving cyclin‐dependent kinase inhibitors

(2019) Lorenzo Gervaso et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study

(2019) Jair Bar et al.   EUROPEAN JOURNAL OF CANCER

Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors

(2019) Yosuke Ando et al.   INVESTIGATIONAL NEW DRUGS

Arterial thrombosis and anti-PD-1 blockade

(2018) Céline Boutros et al.   EUROPEAN JOURNAL OF CANCER

Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: A U.S. Food and Drug Administration pooled analysis.

(2018) Laleh Amiri-Kordestani et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

(2018) Joe-Elie Salem et al.   LANCET ONCOLOGY

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

(2018) Marc Carrier et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Arterial Thromboembolism in Patients With Cancer

(2017) Babak B. Navi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial

(2017) Alok A. Khorana et al.   THROMBOSIS RESEARCH

Venous Thromboembolic Disease

(2017) Michael B. Streiff et al.   Journal of the National Comprehensive Cancer Network

Blood coagulation in immunothrombosis—At the frontline of intravascular immunity

(2016) Florian Gaertner et al.   SEMINARS IN IMMUNOLOGY

Procoagulant and immunogenic properties of melanoma exosomes, microvesicles and apoptotic vesicles

(2016) Morad-Rémy Muhsin-Sharafaldine et al.   Oncotarget

Venous Thromboembolism and Cancer Risk among Elderly Adults in the United States

(2014) M. A. Marks et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Programmed Cell Death-1 Deficiency Exacerbates T Cell Activation and Atherogenesis despite Expansion of Regulatory T Cells in Atherosclerosis-Prone Mice

(2014) Clément Cochain et al.   PLoS One

Venous Thromboembolism Risk in Patients With Cancer Receiving Chemotherapy: A Real-World Analysis

(2013) G. H. Lyman et al.   ONCOLOGIST

Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials

(2012) F. Petrelli et al.   ANNALS OF ONCOLOGY

Smoking and risk of skin cancer: a prospective analysis and a meta-analysis

(2012) F. Song et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Knock-down of plasminogen-activator inhibitor-1 enhances expression of E-cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells

(2012) Monica Lupu-Meiri et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases

(2012) Gladys Alvarado et al.   MELANOMA RESEARCH

Venous thromboembolism in cancer patients – Risk scores and recent randomised controlled trials

(2012) Cihan Ay et al.   THROMBOSIS AND HAEMOSTASIS

Impairment of the Programmed Cell Death-1 Pathway Increases Atherosclerotic Lesion Development and Inflammation

(2011) De-xiu Bu et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Cigarette smoking and the risk of incident and fatal melanoma in a large prospective cohort study

(2011) John Oliver DeLancey et al.   CANCER CAUSES & CONTROL

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)

(2011) Poulam M. Patel et al.   EUROPEAN JOURNAL OF CANCER

Association Between Smoking and Risk of Bladder Cancer Among Men and Women

(2011) Neal D. Freedman   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prediction of venous thromboembolism in cancer patients

(2010) C. Ay et al.   BLOOD

High prevalence and risk factors of thromboembolism in stage IV melanoma

(2010) A Sparsa et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Procoagulant mechanisms in tumour cells

(2009) Anna Falanga et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Development and validation of a predictive model for chemotherapy-associated thrombosis

(2008) A. A. Khorana et al.   BLOOD